window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 3, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Enigma-trs

  • Central Nervous System,Clinical Development,Clinical Trials,Funding

    Newron secures up to EUR 38 million to advance Phase 3 evenamide program in treatment-resistant schizophrenia

    Newron Pharmaceuticals has secured up to EUR 38 million in [...]

    February 16, 2026
  • Central Nervous System,Clinical Development,Clinical studies,Mental health,Neurosciences,Pharmaceuticals and therapeutics

    Newron publishes data showing clinically meaningful benefits of evenamide in treatment-resistant schizophrenia

    Newron Pharmaceuticals has published peer-reviewed clinical data demonstrating that evenamide, [...]

    February 5, 2026
  • Biotech,Central Nervous System,Clinical Development,European biotech,Regulatory Affairs

    Single-cell analysis highlights molecular subgroups in endometriosis that could inform clinical trials

    Endometriosis is typically treated as a single condition, yet patients [...]

    January 7, 2026
  • Biotech,Central Nervous System,Clinical Development,European biotech,Regulatory Affairs

    Newron expands evenamide IP protection with new EU composition of matter patent

    Newron has expanded the intellectual property protection for its lead [...]

    January 6, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Strategies to extend ketamine antidepressant effects identified in new study
    Categories: Central Nervous System, Mental health, Neurosciences, Research & Development
  • Bullfrog AI signs commercial agreement with top 5 global pharma company to identify novel target in major depressive disorder
    Categories: Artificial Intelligence, Digital Health, Mental health, Neurosciences, Research & Development
  • Bio-Sourcing and Tiny Cargo partner to develop oral monoclonal antibodies using milk exosomes
    Categories: Biotech, Drug Delivery & Formulation, Drug Development, Partnerships & Funding, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top